Immuneering Corp (IMRX)
1.64
+0.08
(+5.13%)
USD |
NASDAQ |
May 03, 16:00
1.64
0.00 (0.00%)
After-Hours: 20:00
Immuneering Cash from Financing (Quarterly): 0.0078M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.0078M |
| September 30, 2023 | 0.0214M |
| June 30, 2023 | 28.17M |
| March 31, 2023 | 0.2394M |
| December 31, 2022 | -0.1847M |
| September 30, 2022 | -0.0172M |
| June 30, 2022 | 0.0278M |
| March 31, 2022 | 0.1931M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.0075M |
| September 30, 2021 | 118.49M |
| June 30, 2021 | 25.77M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 36.98M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.9983M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.1847M
Minimum
Dec 2022
118.49M
Maximum
Sep 2021
13.17M
Average
0.0246M
Median
Cash from Financing (Quarterly) Benchmarks
| Geron Corp | 147.80M |
| SELLAS Life Sciences Group Inc | 3.386M |
| Elicio Therapeutics Inc | -- |
| Vistagen Therapeutics Inc | 93.52M |
| ADMA Biologics Inc | -38.99M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -11.78M |
| Cash from Investing (Quarterly) | 3.133M |
| Free Cash Flow | -49.31M |
| Free Cash Flow Per Share (Quarterly) | -0.408 |
| Free Cash Flow Yield | -105.8% |